ICER finds asthma mAbs to be not cost-effective

In a draft evidence report, the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies despite all showing comparable or better efficacy to SOC.

The review evaluated benefits and costs associated with Dupixent dupilumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN); Xolair omalizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQB:RHHBY) and Novartis AG (NYSE:NVS; SIX:NOVN); Nucala mepolizumab from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK); Cinqair reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA); and Fasenra benralizumab from Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) and AstraZeneca plc (LSE:AZN; NYSE:AZN). The institute reviewed patient health outcomes associated with the medicines, including quality of life (QOL), asthma control and exacerbations, hospitalizations, harms, mortality and oral steroid use...